Ypsomed Holding stock

YPSN · SIX · CHF

Compare Ypsomed Holding
CHF 421.80Change from previous close: −1.63%Absolute change: −CHF 7.00

Close · November 17, 2026

Price history

+30.52% over the period

1 year: from CHF 327.00 (November 17, 2025) to CHF 426.80 (November 17, 2026), +30.52%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026CHF 426.80
October 30, 2026CHF 394.80
September 30, 2026CHF 366.00
August 31, 2026CHF 397.80
July 31, 2026CHF 385.20
June 30, 2026CHF 364.80
May 29, 2026CHF 350.40
April 30, 2026CHF 273.00
March 31, 2026CHF 276.00
February 27, 2026CHF 267.00
January 30, 2026CHF 305.50
December 30, 2025CHF 328.00
November 28, 2025CHF 330.50
November 17, 2025CHF 327.00

At a glance

  • The company

    Develops, manufactures and sells injection and infusion systems for self-medication across hospitals, doctors, pharmacies and patients

  • Latest results

    Quarter to March 31, 2026 · EPS CHF 6.10 (estimate CHF 6.92)

TickerLandia's take on Ypsomed Holding

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 260.50
52-wk highCHF 437.60

−3.61% from the 52-week high

Analysts · 14 analysts

Average targetCHF 413.71−1.92% vs. price

Buy 8 · Hold 4 · Sell 2 · Buy

TickerLandia Fingerprint: Ypsomed Holding

Compared with similar companies: very high profitability.

Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Ypsomed Holding is cheaper than in the past and in line with similar companies

On the latest fiscal year's earnings (2026), Ypsomed Holding's P/E today is 26.2, below the median of its last 9 fiscal years (51.8; between 16.9 and 133.8 from 2017 to 2026). Ypsomed Holding's P/E (trailing 12 months): 34.3, in line with the median of a group of 10 similar companies (34.3).

P/E compared with its history

Compared with 10 similar companies

Ypsomed Holding's metrics compared with similar companies
MetricYpsomed HoldingPosition in the groupBand
P/E (trailing 12 months)34.3Middle
Forward P/E29.0Middle
Operating margin36.2%High
ROE31.1%High
Debt/equity0.35Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Ypsomed Holding. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

CHF 368.29M

Latest quarter · Q1 2026

Net income

CHF 82.83M

Latest quarter · Q1 2026

Quarterly net margin

22.5%

Latest quarter · Q1 2026

Numbers and valuation

Full valuation
Market cap
CHF 5.68B
P/E
34.3
EPS
CHF 12.61
Volume
3.02K
Daily trading
€7.45M
Dividend yield
1.04%
Last ex-dividend on July 3, 2026

How Ypsomed Holding is changing

All results
  • Revenue grew 12.6% a year on average over the last 5 years

  • Operating margin rose from 8.7% to 36.2%

  • Less cash than profit: free cash flow equal to 0% of net income

Returns

Ypsomed Holding returns with dividends

CHF 1,000 invested in Ypsomed Holding 5 years ago, on November 17, 2021, would be worth CHF 2,393 today with dividends reinvested: +139.30% in total, +19.07% per year. On price alone it would be CHF 2,307 (+130.66%).

PeriodYpsomed HoldingSMICHF 1,000 becomes
1 month+13.39%+4.53%CHF 1,134
6 months+42.21%+13.61%CHF 1,422
Year to date+30.12%+13.20%CHF 1,301
1 year+32.12%+19.22%CHF 1,321
3 years+59.29%+39.88%CHF 1,593
5 years+139.30%+19.20%CHF 2,393
10 years+153.25%+88.57%CHF 2,533

Over the last 6 months it has done better than 64% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment

The chart in detail

Ypsomed Holding: technical analysis

Ypsomed Holding is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 3.5% below its all-time closing high (CHF 437.20, November 12, 2026).

Trend
Upward
RSI (14 sessions)
65
Between 30 and 70
vs 200-session average
+22.69%

Support and resistance

Price areas where Ypsomed Holding has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last priceCHF 421.80
  3. SupportCHF 417.00−1.14%3 touches, last on September 3, 2026
  4. SupportCHF 371.27−11.98%3 touches, last on September 24, 2026
  5. SupportCHF 355.12−15.81%6 touches, last on October 8, 2026

Volatility and risk

Over the last year it has moved less than the SMI.

Beta (1 year) vs SMI
0.68
Volatility (60 sessions, annualised)
30.3%
Largest fall in the last year
−23.61%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Ypsomed Holding: seasonality

Average monthly price change over 23 years

+2.5%Jan−0.4%Feb+0.9%Mar+0.1%Apr+4.0%May+0.1%Jun−1.7%Jul+1.9%Aug−3.0%Sep+2.0%Oct+4.8%Nov+0.6%Dec

Over the last 23 years, the strongest month for Ypsomed Holding has been November: +4.78% on average, positive in 14 years out of 22. The weakest has been September: −3.03% on average, positive in 8 years out of 22.

Show chart data
MonthAverageMedianPositive years
January+2.52%+1.08%12 of 22
February−0.42%−1.66%9 of 22
March+0.86%+0.57%13 of 22
April+0.06%+0.05%11 of 22
May+4.02%+4.18%13 of 22
June+0.05%−0.80%10 of 22
July−1.68%−0.35%8 of 22
August+1.86%+1.56%13 of 22
September−3.03%−0.90%8 of 22
October+2.01%+1.45%13 of 23
November+4.78%+1.24%14 of 22
December+0.65%−0.51%9 of 22

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Ypsomed Holding and its competitors

Sales reach Switzerland, Europe, North America and other markets worldwide, where the group develops, manufactures and sells systems that allow patients to administer medication themselves. Its range covers pen injectors, auto-injectors and wearable injectors, together with related services, and it also makes infusion sets and reservoirs under contract. Products are marketed to hospitals, doctors, pharmacies and patients through subsidiaries and distributors.

Headquarters
Burgdorf, Switzerland
Employees
2,025
Founded
1984
Chief executive
Simon Michel
Ypsomed Holding and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Ypsomed HoldingYPSN$6.76B36.2%34.3+42.21%
ConvaTec GroupCTEC$6.51B16.3%51.6+18.65%
Fielmann GroupFIE$4.05B13.7%16.9+1.29%
SCHOTT Pharma1SXP$3.69B16.4%24.8+37.06%
Tecan GroupTECN$3.65B4.9%—+72.98%
Carl Zeiss MeditecAFX$3.37B7.2%25.2+38.26%

Same industry or related industries, similar size. Compare Ypsomed Holding with its competitors · Full profile